ArticleFrontiers in immunology2025
Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Two Flavones as Markers for the Distinction of Natural Acacia Honey Based on the UHPLC-QE-MS Method and Research on Their Potential Immunomodulatory Activity.Food science & nutrition · 2026Article
- Could CT spleen volumetry be a novel biomarker for predicting renal graft function?Abdominal radiology (New York) · 2026Article
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- NG25 Enhances Anti-Tumor Immunity inOncoTargets and therapy · 2026Article
- Adiposity, mortality, and disease risk: insights from bioimpedance analysis and magnetic resonance imaging.BMC medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This investigation seeks to examine the association between spleen volume and prognosis in cancer patients undergoing immune checkpoint inhibitor (ICI) treatment. Methods: We performed a retrospective analysis involving 61 patients diagnosed with hepatocellular carcinoma (HCC) who received ICIs at our institution. We evaluated the relationship between baseline splenic volume and its changes during ICI therapy concerning overall survival (OS) and progression-free survival (PFS) using a log-rank test. To identify relevant literature, we searched databases such as PubMed, EMBASE, the Cochrane Library, and Google Scholar up until February 20, 2024. The primary metrics assessed were hazard ratios (HR) for both OS and PFS, with pooled estimates and corresponding 95% confidence intervals (CIs) calculated. Results: Within our study population, findings demonstrated a significantly decreased OS (HR: 2.02, 95% CI: 1.08-3.77, Conclusion: A higher baseline spleen volume and an increase in spleen volume during ICI therapy were predictors of a poor prognosis in cancer patients treated with ICI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.